Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.

ABSTRACT:

Aim

Interleukin (IL)-7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an IL-7 receptor-α subunit (CD127) monoclonal antibody.

Methods

A double-blind (sponsor-unblind) study of a single intravenous infusion of either GSK2618960 (0.6 mg kg^-1 or 2.0 mg kg^-1 ) or placebo was carried out in 18 healthy subjects over 24 weeks.

Results

GSK2618960 was well tolerated; there were no serious or significant adverse events. The observed half-life was 5 (±1) days (2.0 mg kg^-1 ), with nonlinear pharmacokinetics. Full receptor occupancy (>95%) was observed until day 8 (0.6 mg kg

SUBMITTER: Ellis J 

PROVIDER: S-EPMC6339973 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature